On June 17, 2019 TG Therapeutics, Inc. (NASDAQ: TGTX) reported the presentation of preclinical data for TG-1801, the Company’s first-in-class anti-CD47/CD19 bispecific antibody, highlighting the synergistic effect of TG-1801 in combination with ublituximab, the Company’s anti-CD20 monoclonal antibody and umbralisib, the Company’s PI3K-delta inhibitor (Press release, TG Therapeutics, JUN 17, 2019, View Source [SID1234537110]). These data were presented over the weekend at the 24thEuropean Hematology Association (EHA) (Free EHA Whitepaper) annual congress held in Amsterdam, The Netherlands.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from this poster presentation include:
Title: The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL
TG-1801 is a first-in-class anti-CD47-CD19 bispecific antibody that selectively targets CD47 on CD19+ B-cells, sparing red blood cells and platelets, and blocking the CD47-SIRPα macrophage checkpoint on mature B cells
Ublituximab exerts stronger ADCP and ADCC activity in B-NHL cells when compared to rituximab, and TG-1801 increased the ADCC and ADCP activities initiated by both ublituximab and the U2 combination
The triple combination of TG-1801 + U2 was found to regulate genes related to cell architecture
TG-1801 triggers synergistic tumor growth inhibition and results in prolonged remission when added to U2 in an in vivo Raji lymphoma model, which appears to be mediated by increased infiltration of immune effector cells
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, "TG-1801 is a first-in-class anti-CD47/CD19 bispecific antibody targeting the ‘don’t eat me’ self-defense signal that protects cancer cells from the immune system. This agent is designed to target CD19 expressing cells to avoid off-target CD47 toxicity, representing a novel immunological therapeutic strategy with potential for synergistic or complimentary activity with our current pipeline." Mr. Weiss continued, "We are excited by the preclinical data presented today for TG-1801. The synergistic effects of TG-1801 in combination with U2 are encouraging and we look forward to evaluating TG-1801 as a single agent in our on-going TG-1801 Phase 1 clinical study and as soon as possible in combination with U2 and our other pipeline drug candidates. TG is committed to improving the outcome of patients with B-cell malignancies through combination therapy and we believe TG-1801 may play an important role in that effort."
PRESENTATION DETAILS:
The above referenced presentation is available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.